The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding
- PMID: 16198295
- DOI: 10.1016/j.devcel.2005.09.008
The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding
Abstract
TGF-beta ligands stimulate diverse cellular differentiation and growth responses by signaling through type I and II receptors. Ligand antagonists, such as follistatin, block signaling and are essential regulators of physiological responses. Here we report the structure of activin A, a TGF-beta ligand, bound to the high-affinity antagonist follistatin. Two follistatin molecules encircle activin, neutralizing the ligand by burying one-third of its residues and its receptor binding sites. Previous studies have suggested that type I receptor binding would not be blocked by follistatin, but the crystal structure reveals that the follistatin N-terminal domain has an unexpected fold that mimics a universal type I receptor motif and occupies this receptor binding site. The formation of follistatin:BMP:type I receptor complexes can be explained by the stoichiometric and geometric arrangement of the activin:follistatin complex. The mode of ligand binding by follistatin has important implications for its ability to neutralize homo- and heterodimeric ligands of this growth factor family.
Similar articles
-
A molecular recognition paradigm: promiscuity associated with the ligand-receptor interactions of the activin members of the TGF-beta superfamily.J Mol Recognit. 2005 Sep-Oct;18(5):385-403. doi: 10.1002/jmr.715. J Mol Recognit. 2005. PMID: 15948132 Review.
-
Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex.Nat Struct Biol. 2002 Mar;9(3):203-8. doi: 10.1038/nsb766. Nat Struct Biol. 2002. PMID: 11850637
-
Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.J Mol Biol. 2005 Dec 16;354(5):1052-68. doi: 10.1016/j.jmb.2005.10.014. Epub 2005 Oct 27. J Mol Biol. 2005. PMID: 16289576
-
Structural basis for the inhibition of activin signalling by follistatin.EMBO J. 2006 Mar 8;25(5):1035-45. doi: 10.1038/sj.emboj.7601000. Epub 2006 Feb 16. EMBO J. 2006. PMID: 16482217 Free PMC article.
-
Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.Nat Struct Biol. 1999 Jan;6(1):18-22. doi: 10.1038/4887. Nat Struct Biol. 1999. PMID: 9886286 Review.
Cited by
-
Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism.Structure. 2013 Aug 6;21(8):1417-29. doi: 10.1016/j.str.2013.06.005. Epub 2013 Jul 11. Structure. 2013. PMID: 23850456 Free PMC article.
-
Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.Mol Endocrinol. 2012 Jul;26(7):1167-78. doi: 10.1210/me.2012-1061. Epub 2012 May 16. Mol Endocrinol. 2012. PMID: 22593183 Free PMC article.
-
Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.Cancers (Basel). 2014 Dec 30;7(1):70-91. doi: 10.3390/cancers7010070. Cancers (Basel). 2014. PMID: 25560921 Free PMC article. Review.
-
Genome-wide host responses against infectious laryngotracheitis virus vaccine infection in chicken embryo lung cells.BMC Genomics. 2012 Apr 24;13:143. doi: 10.1186/1471-2164-13-143. BMC Genomics. 2012. PMID: 22530940 Free PMC article.
-
Neuroendocrine control of FSH secretion: IV. Hypothalamic control of pituitary FSH-regulatory proteins and their relationship to changes in FSH synthesis and secretion.Biol Reprod. 2012 Jun 7;86(6):171. doi: 10.1095/biolreprod.111.098442. Print 2012 Jun. Biol Reprod. 2012. PMID: 22423050 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases